KLOW (BPC+TB+GHK+KPV)

KLOW Blend (GHK-Cu + BPC-157 + TB-500 + KPV)

The KLOW blend is a lyophilized four-peptide research blend. It contains the same three peptides as our GLOW blend (GHK-Cu, BPC-157 and TB-500) and adds KPV, the Lys-Pro-Val tripeptide from the C-terminus of α-melanocyte-stimulating hormone. KPV brings an inflammation-signaling component that the other three lack, which is the main reason laboratories choose this four-way format.

Product Specifications

• Product: KLOW (GHK-Cu + BPC-157 + TB-500 + KPV)
• Amount: See available options above
• Form: Lyophilized powder
• Purity: Third-party tested by an ISO 17025 U.S. laboratory. See the batch Certificate of Analysis (COA) on this page.
• Storage: Keep sealed and refrigerated at 2–8°C (36–46°F), protected from light.
• Ships from: United States, 2-day UPS

Composition

• GHK-Cu: copper(II) complex of Gly-His-Lys; CAS 89030-95-5
• BPC-157: synthetic pentadecapeptide; CAS 137525-51-0
• TB-500: synthetic peptide related to thymosin β4
• KPV: tripeptide Lys-Pro-Val (α-MSH 11–13); CAS 67727-97-3
• Amount of each peptide per vial: stated on the vial label and the batch Certificate of Analysis

What researchers study

Each ingredient maps to a different research question:

• KPV: in intestinal epithelial cells KPV is taken up through the di/tripeptide transporter PepT1, and in mouse colitis models it has been studied for its effects on NF-κB and inflammatory cytokine signaling.
• GHK-Cu: copper delivery, fibroblast matrix synthesis and genome-wide expression changes.
• BPC-157: alkali-burn wound models in rats and endothelial proliferation, migration and tube-formation assays.
• Thymosin β4: rodent dermal, corneal and cardiac repair models and actin regulation.

Published work on these peptides is almost entirely in cell culture and animal models, and no peer-reviewed study has examined all four together. The literature below describes the individual ingredients. Researchers working with the blend typically need component-resolved analytical methods, since the four peptides differ widely in size, from a 3-residue peptide to a 43-residue thymosin.

Regulatory status

None of the four components is approved by the FDA as a drug. On the World Anti-Doping Agency’s Prohibited List, BPC-157 falls under S0 and thymosin-β4 derivatives such as TB-500 are named under S2. KLOW is sold as a research reagent only.

Quality & Documentation

Every batch of KLOW is made in small runs for Rogue Compounds and tested by an independent U.S. laboratory for identity and concentration. Each vial is labeled with its batch number and a QR code that opens the testing lab’s own report for that batch. The same batch Certificate of Analysis is posted on this page and in our COA Library, so you can check one against the other.

Selected literature

• Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci. 2018;19(7):1987. PMID 29986520
• Dalmasso G, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178. PMID 18061177
• Huang T, et al. Body protective compound-157 enhances alkali-burn wound healing in vivo and promotes proliferation, migration, and angiogenesis in vitro. Drug Des Devel Ther. 2015;9:2485-2499. PMID 25995620
• Philp D, Kleinman HK. Animal studies with thymosin beta, a multifunctional tissue repair and regeneration peptide. Ann N Y Acad Sci. 2010;1194:81-86. PMID 20536453

Research Use Only

This product is sold strictly as a research chemical for in-vitro laboratory and analytical use by qualified professionals. It is not a drug, dietary supplement, food, or cosmetic, and it is not intended to diagnose, treat, cure, or prevent any disease. Not for human or veterinary use. Rogue Compounds does not provide dosing, preparation, or usage instructions. The literature on this page is listed for scientific background only and does not describe this product or any use of it.